J Clin Immunol. 2026 Mar 21. doi: 10.1007/s10875-026-02005-1. Online ahead of print. NO ABSTRACT PMID:41863683 | DOI:10.1007/s10875-026-02005-1
J Clin Immunol. 2026 Mar 21. doi: 10.1007/s10875-026-02004-2. Online ahead of print. NO ABSTRACT PMID:41863562 | DOI:10.1007/s10875-026-02004-2
J Clin Immunol. 2026 Mar 14. doi: 10.1007/s10875-026-01995-2. Online ahead of print. ABSTRACT TREC-NBS identifies patients with inborn errors of immunity (IEI) and syndromic features, but uncertainty remains regarding their immunological management. To address this, syndromic patients detected by TREC-NBS in Germany between August 2019 and April 2024 were systematically analyzed, including phenotype, treatment, and … Read more
J Clin Immunol. 2026 Mar 7. doi: 10.1007/s10875-026-02002-4. Online ahead of print. NO ABSTRACT PMID:41793545 | DOI:10.1007/s10875-026-02002-4
J Clin Immunol. 2026 Mar 7. doi: 10.1007/s10875-026-02000-6. Online ahead of print. NO ABSTRACT PMID:41795040 | DOI:10.1007/s10875-026-02000-6
J Clin Immunol. 2026 Mar 6. doi: 10.1007/s10875-026-01989-0. Online ahead of print. NO ABSTRACT PMID:41790376 | DOI:10.1007/s10875-026-01989-0
J Clin Immunol. 2026 Mar 4;46(1):23. doi: 10.1007/s10875-026-01988-1. NO ABSTRACT PMID:41781714 | DOI:10.1007/s10875-026-01988-1
J Clin Immunol. 2026 Mar 2. doi: 10.1007/s10875-026-01994-3. Online ahead of print. ABSTRACT AIM: Idiopathic nephrotic syndrome (INS) is the most common glomerular disease in children, but its underlying mechanisms remain unclear. Although glucocorticoids (GC) are the first-line treatment, approximately 10% of INS cases are steroid-resistant (SRNS), and 50% may progress to refractory nephrotic syndrome … Read more
J Clin Immunol. 2026 Feb 28. doi: 10.1007/s10875-026-01985-4. Online ahead of print. NO ABSTRACT PMID:41762359 | DOI:10.1007/s10875-026-01985-4
J Clin Immunol. 2026 Feb 26. doi: 10.1007/s10875-026-01990-7. Online ahead of print. NO ABSTRACT PMID:41746515 | DOI:10.1007/s10875-026-01990-7
